Colorectal Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colorectal Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 1 (2004), Issue 4 (November)

1. Trophoblastic tissue spread to the sigmoid colon after uterine perforation.
   Obstet Gynecol, 104(5): 1172-4. [Abstract] [Full-text]
2. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
   J Surg Oncol, 88(2): 78-85. [Abstract] [Full-text]
3. Resection of the rectum and total excision of the internal anal sphincter with smooth muscle plasty and colonic pouch for treatment of ultralow rectal carcinoma.
   Br J Surg, 91(11): 1506-12. [Abstract] [Full-text]
4. Abdominoperineal resection is associated with poor oncological outcome.
   Br J Surg, 91(11): 1493-9. [Abstract] [Full-text]
5. High-level mRNA quantification of proliferation marker pKi-67 is correlated with favorable prognosis in colorectal carcinoma.
   J Cancer Res Clin Oncol, 130(12): 749-56. [Abstract] [Full-text]
6. Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras, and p53 genes.
   Virchows Arch, 445(5): 465-71. [Abstract] [Full-text]
7. Dietary factors and truncating APC mutations in sporadic colorectal adenomas.
   Int J Cancer, 113(1): 126-32. [Abstract] [Full-text]
8. p21(Waf1/Cip1) and p53 are downstream effectors of protein kinase C delta in tumor suppression and differentiation in human colon cancer cells.
   Int J Cancer, 113(1): 42-53. [Abstract] [Full-text]
9. Interobserver variability in the pathological assessment of malignant colorectal polyps.
   Br J Surg, 91(11): 1479-84. [Abstract] [Full-text]
10. Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis.
    Virchows Arch, 445(5): 456-64. [Abstract] [Full-text]
11. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan.
    J Cancer Res Clin Oncol, 130(12): 728-32. [Abstract] [Full-text]
12. Reduced levels of the adenomatous polyposis coli (APC) protein are associated with ceramide-induced apoptosis of colon cancer cells.
    J Cancer Res Clin Oncol, 130(12): 695-703. [Abstract] [Full-text]
13. Autocrine transforming growth factor alpha regulates cell adhesion by multiple signaling via specific phosphorylation sites of p70S6 kinase in colon cancer cells.
    J Biol Chem, 279(45): 47379-90. [Abstract] [Full-text]
14. Measuring tumor volume with three-dimensional endoscopic ultrasonography: an experimental and clinical study (including video).
    Endoscopy, 36(11): 976-81. [Abstract] [Full-text]
15. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53.
    Cancer Res, 64(21): 8015-21. [Abstract] [Full-text]
16. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
    Cancer Res, 64(21): 7690-6. [Abstract] [Full-text]
17. Efficacy of orgotein in prevention of late side effects of pelvic irradiation: a randomized study.
    Int J Radiat Oncol Biol Phys, 60(4): 1211-9. [Abstract] [Full-text]
18. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
    Int J Radiat Oncol Biol Phys, 60(4): 1098-105. [Abstract] [Full-text]
19. Equivalence test in quantitative reverse transcription polymerase chain reaction: confirmation of reference genes suitable for normalization.
    Anal Biochem, 335(1): 1-9. [Abstract] [Full-text]
20. Familial association of colorectal adenocarcinoma with cancers at other sites.
    Eur J Cancer, 40(16): 2480-7. [Abstract] [Full-text]
21. Incremental value of CT in PET/CT of patients with colorectal carcinoma.
    Abdom Imaging, 29(6): 663-8. [Abstract] [Full-text]
22. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk.
    J Natl Cancer Inst, 96(21): 1631-4. [Abstract] [Full-text]
23. Dietary fat and fatty acids and risk of colorectal cancer in women.
    Am J Epidemiol, 160(10): 1011-22. [Abstract] [Full-text]
24. Small but significant survival benefit in patients who undergo routine follow-up after colorectal cancer surgery.
    Eur J Surg Oncol, 30(10): 1093-7. [Abstract] [Full-text]
25. Hyaluronan mediates adhesion of metastatic colon carcinoma cells.
    J Surg Res, 122(1): 70-4. [Abstract] [Full-text]
26. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas.
    Biochem Biophys Res Commun, 325(1): 144-50. [Abstract] [Full-text]
27. Absence of socioeconomic variation in survival from colorectal cancer in patients receiving surgical treatment in one health district: cohort study.
    Colorectal Dis, 6(6): 512-7. [Abstract] [Full-text]
28. Risk factors for anastomotic leakage after anterior resection of the rectum.
    Colorectal Dis, 6(6): 462-9. [Abstract] [Full-text]
29. Blood loss and transfusion after total mesorectal excision and conventional rectal cancer surgery.
    Colorectal Dis, 6(6): 452-7. [Abstract] [Full-text]
30. Local resection of rectal tumours using the Salvati operating proctoscope--a safe and effective technique.
    Colorectal Dis, 6(6): 446-51. [Abstract] [Full-text]
31. Residual urine volume after total mesorectal excision: an indicator of pelvic autonomic nerve preservation? Results of a case-control study.
    Colorectal Dis, 6(6): 432-7. [Abstract] [Full-text]
32. A study on the routes of referral for patients with colorectal cancer and its affect on the time to surgery and pathological stage.
    Colorectal Dis, 6(6): 428-31. [Abstract] [Full-text]
33. Impact of national guidelines about the management of colorectal cancer on Australian surgeons' awareness of evidence: a pre/post survey.
    Colorectal Dis, 6(6): 418-27. [Abstract] [Full-text]
34. Developments in treatment of primary irresectable rectal cancer.
    Colorectal Dis, 6(6): 406-17. [Abstract] [Full-text]
35. Inflammatory bowel diseases as an intermediate stage between normal and cancer: a FTIR-microspectroscopy approach.
    Biopolymers, 75(5): 384-92. [Abstract] [Full-text]
36. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases.
    Ann Surg Oncol, 11(11): 977-82. [Abstract] [Full-text]
37. Institutional commitment to rectal cancer screening results in earlier-stage cancers on diagnosis.
    Ann Surg Oncol, 11(11): 970-6. [Abstract] [Full-text]
38. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome.
    Ann Surg Oncol, 11(11): 955-61. [Abstract] [Full-text]
39. Transthoracic percutaneous radiofrequency ablation for liver tumors in the hepatic dome.
    J Vasc Interv Radiol, 15(11): 1323-7. [Abstract] [Full-text]
40. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
    Oncogene, 23(52): 8464-74. [Abstract] [Full-text]
41. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
    Cancer Chemother Pharmacol, 54(6): 531-6. [Abstract] [Full-text]
42. An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
    Invest New Drugs, 23(1): 63-71. [Abstract] [Full-text]
43. The emerging role of virtual colonoscopy.
    Med Clin North Am, 89(1): 111-38, viii. [Abstract] [Full-text]
44. Prevention and therapy of colorectal cancer.
    Med Clin North Am, 89(1): 85-110, viii. [Abstract] [Full-text]
45. Surveillance of patients at high risk for colorectal cancer.
    Med Clin North Am, 89(1): 61-84, vii-viii. [Abstract] [Full-text]
46. Screening of patients at average risk for colon cancer.
    Med Clin North Am, 89(1): 43-59, vii. [Abstract] [Full-text]
47. The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps.
    Med Clin North Am, 89(1): 1-42, vii. [Abstract] [Full-text]
48. Ethanol acts as a potent agent sensitizing colon cancer cells to the TRAIL-induced apoptosis.
    FEBS Lett, 577(1): 309-13. [Abstract] [Full-text]
49. Hepatic resection for colorectal metastases - a national perspective.
    Ann R Coll Surg Engl, 86(6): 420-4. [Abstract] [Full-text]
50. Preoperative local staging of rectal cancer with endorectal MR imaging: comparison with histopathologic findings.
    Clin Imaging, 28(6): 432-8. [Abstract] [Full-text]
51. Barium enema "shoulder" sign: a useful predictor of pericolonic fat invasion in colorectal cancer.
    Clin Imaging, 28(6): 428-31. [Abstract] [Full-text]
52. Predictive testing for hereditary non-polyposis colorectal cancer: motivation, illness representations and short-term psychological impact.
    Patient Educ Couns, 55(2): 265-74. [Abstract] [Full-text]
53. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Cancer, 101(10): 2170-6. [Abstract] [Full-text]
54. Morbidity and mortality of colorectal carcinoma surgery differs by insurance status.
    Cancer, 101(10): 2187-94. [Abstract] [Full-text]
55. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases.
    Clin Cancer Res, 10(21): 7318-28. [Abstract] [Full-text]
56. Topoisomerase II gene mutations in tumors and tumor cell lines with microsatellite instability.
    Cancer Lett, 216(2): 221-6. [Abstract] [Full-text]
57. Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risks of colon and rectal cancers in Korea.
    Cancer Lett, 216(2): 199-205. [Abstract] [Full-text]
58. Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells.
    Biochim Biophys Acta, 1675(1): 113-9. [Abstract] [Full-text]
59. Multiple rare variants in different genes account for multifactorial inherited susceptibility to colorectal adenomas.
    Proc Natl Acad Sci U S A, 101(45): 15992-7. [Abstract] [Full-text]
60. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
    Br J Cancer, 91(10): 1758-62. [Abstract] [Full-text]
61. Anatomical distribution of colorectal cancer over a 10 year period in a district general hospital: is there a true "rightward shift"?
    Postgrad Med J, 80(949): 667-9. [Abstract] [Full-text]
62. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer.
    Prostate, 62(1): 101-4. [Abstract] [Full-text]
63. Determination of carcinoembryonic antigen levels in peripheral and draining venous blood in patients with colorectal carcinoma.
    Arq Gastroenterol, 41(2): 88-92. [Abstract] [Full-text]
64. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.
    J Clin Oncol, 22(22): 4584-94. [Abstract] [Full-text]
65. Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation.
    Gut, 53(12): 1832-6. [Abstract] [Full-text]
66. Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.
    Gut, 53(12): 1825-31. [Abstract] [Full-text]
67. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk.
    Gut, 53(12): 1813-6. [Abstract] [Full-text]
68. High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma.
    Radiother Oncol, 73(2): 195-8. [Abstract] [Full-text]
69. Genomic heterogeneity and instability in colorectal cancer: spectral karyotyping, glutathione transferase-Ml and ras.
    Mutat Res, 568(2): 283-92. [Abstract] [Full-text]
70. Clinicopathologic features in colorectal cancer patients with microsatellite instability.
    Mutat Res, 568(2): 275-82. [Abstract] [Full-text]
71. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.
    Biochem Biophys Res Commun, 325(3): 784-91. [Abstract] [Full-text]
72. Unique TCRDV1-positive lymphocytes that infiltrate colonic neoplasia originate from a selected cell population present in the intestinal mucosa and the peripheral blood.
    Scand J Immunol, 60(5): 529-34. [Abstract] [Full-text]
73. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
    J Clin Oncol, 22(22): 4456-62. [Abstract] [Full-text]
74. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
    J Clin Oncol, 22(22): 4486-94. [Abstract] [Full-text]
75. 1% lymphazurin vs 10% fluorescein for sentinel node mapping in colorectal tumors.
    Arch Surg, 139(11): 1180-4. [Abstract] [Full-text]
76. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases.
    Arch Surg, 139(11): 1168-72. [Abstract] [Full-text]
77. Portal and systemic serum growth factor and acute-phase response after laparotomy or partial hepatectomy in patients with colorectal liver metastases: a prognostic role for C-reactive protein and hepatocyte growth factor.
    Scand J Gastroenterol, 39(11): 1141-8. [Abstract] [Full-text]
78. Genetic characterization of colorectal cancers in young patients based on chromosomal loss and microsatellite instability.
    Scand J Gastroenterol, 39(11): 1134-40. [Abstract] [Full-text]
79. Low electric field enhanced chemotherapy can cure mice with CT-26 colon carcinoma and induce anti-tumour immunity.
    Clin Exp Immunol, 138(3): 410-6. [Abstract] [Full-text]
80. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers.
    Lab Invest, 84(12): 1619-30. [Abstract] [Full-text]
81. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Ann Oncol, 15(12): 1766-72. [Abstract] [Full-text]
82. The influence of training level and surgical experience on survival in colorectal cancer.
    Langenbecks Arch Surg, 389(6): 524-31. [Abstract] [Full-text]
83. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.
    Cancer Res, 64(22): 8156-9. [Abstract] [Full-text]
84. Extracellular pressure stimulates colon cancer cell proliferation via a mechanism requiring PKC and tyrosine kinase signals.
    Cell Prolif, 37(6): 427-41. [Abstract] [Full-text]
85. Selenium and colorectal adenoma: results of a pooled analysis.
    J Natl Cancer Inst, 96(22): 1669-75. [Abstract] [Full-text]
86. Extracellular pressure stimulates colon cancer cell adhesion in vitro and to surgical wounds by Src (sarcoma protein) activation.
    Am J Surg, 188(5): 467-73. [Abstract] [Full-text]
87. Influence of individually estimated portion size on the assessment of nutritional risk in colorectal cancer in Portugal.
    J Hum Nutr Diet, 17(6): 529-36. [Abstract] [Full-text]
88. A longitudinal analysis of the course of depressive symptomatology in geriatric patients with cancer of the breast, colon, lung, or prostate.
    Health Psychol, 23(6): 564-73. [Abstract] [Full-text]
89. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    J Pathol, 204(5): 562-8. [Abstract] [Full-text]
90. Overweight, obesity, and colorectal cancer screening: disparity between men and women.
    BMC Public Health, 4(1): 53. [Abstract] [Full-text]
91. Combined use of positive and negative immunomagnetic isolation followed by real-time RT-PCR for detection of the circulating tumor cells in patients with colorectal cancers.
    J Mol Med, 82(11): 768-74. [Abstract] [Full-text]
92. ApcMin/+ mouse model of colon cancer: gene expression profiling in tumors.
    J Cell Biochem, 93(6): 1242-54. [Abstract] [Full-text]
93. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma.
    Int J Cancer, 113(2): 198-206. [Abstract] [Full-text]
94. Validation of bioluminescence imaging of colorectal liver metastases in the mouse.
    J Surg Res, 122(2): 225-30. [Abstract] [Full-text]
95. Selective nonsteroidal anti-inflammatory drugs induce thymosin beta-4 and alter actin cytoskeletal organization in human colorectal cancer cells.
    J Pharmacol Exp Ther, 311(3): 885-91. [Abstract] [Full-text]
96. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.
    Br J Cancer, 91(11): 1931-46. [Abstract] [Full-text]
97. A survey of individual preference for colorectal cancer screening technique.
    BMC Cancer, 4: 76. [Abstract] [Full-text]
98. A population-based study of colorectal cancer test use: results from the 2001 California Health Interview Survey.
    Cancer, 101(11): 2523-32. [Abstract] [Full-text]
99. Two schedules of second-line irinotecan for metastatic colon carcinoma.
    Cancer, 101(11): 2533-9. [Abstract] [Full-text]
100. nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma.
     J Clin Pathol, 57(12): 1312-8. [Abstract] [Full-text]
101. The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase-1 in DLD-1 colon carcinoma cells.
     Br J Pharmacol, 143(7): 890-8. [Abstract] [Full-text]
102. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
     Radiology, 233(3): 729-39. [Abstract] [Full-text]
103. Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter.
     Mol Ther, 10(6): 1043-50. [Abstract] [Full-text]
104. The consistency of panelists' appropriateness ratings: do experts produce clinically logical scores for rectal cancer treatment?
     Health Policy, 71(1): 57-65. [Abstract] [Full-text]
105. Age-related loss of EGF-receptor related protein (ERRP) in the aging colon is a potential risk factor for colon cancer.
     Mech Ageing Dev, 125(12): 917-22. [Abstract] [Full-text]
106. Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers.
     J Cancer Res Clin Oncol, 131(1): 49-59. [Abstract] [Full-text]
107. Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors.
     Oncogene, 23(55): 8900-7. [Abstract] [Full-text]
108. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells.
     Oncogene, 23(55): 8979-86. [Abstract] [Full-text]
109. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
     Oncogene, 23(55): 8876-86. [Abstract] [Full-text]
110. JTE-522, a selective cyclooxygenase-2 inhibitor, inhibits induction but not growth and invasion of 1,2-dimethylhydrazine-induced tubular adenocarcinomas of colon in rats.
     Int J Cancer, 113(3): 354-8. [Abstract] [Full-text]
111. Mononucleotide repeats BAT-26 and BAT-25 accurately detect MSI-H tumors and predict tumor content: implications for population screening.
     Int J Cancer, 113(3): 446-50. [Abstract] [Full-text]
112. Mutational analysis of OGG1, MYH, MTH1 in FAP, HNPCC and sporadic colorectal cancer patients: R154H OGG1 polymorphism is associated with sporadic colorectal cancer patients.
     Hum Genet, 115(6): 498-503. [Abstract] [Full-text]
113. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
     Cancer Chemother Pharmacol, 55(1): 39-46. [Abstract] [Full-text]
114. Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil.
     Cancer Chemother Pharmacol, 55(1): 12-20. [Abstract] [Full-text]
115. Unexpected Hedgehog-Wnt interactions in epithelial differentiation.
     Trends Mol Med, 10(12): 577-80. [Abstract] [Full-text]
116. Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein.
     Biochem Biophys Res Commun, 326(1): 7-17. [Abstract] [Full-text]
117. Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study.
     J Clin Oncol, 22(23): 4829-36. [Abstract] [Full-text]
118. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
     J Clin Oncol, 22(23): 4772-8. [Abstract] [Full-text]
119. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
     J Clin Oncol, 22(23): 4753-61. [Abstract] [Full-text]
120. Recruitment of patients into an internet-based clinical trials database: the experience of OncoLink and the National Colorectal Cancer Research Alliance.
     J Clin Oncol, 22(23): 4730-6. [Abstract] [Full-text]
121. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose.
     Clin Cancer Res, 10(22): 7520-8. [Abstract] [Full-text]
122. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis.
     Clin Cancer Res, 10(22): 7475-83. [Abstract] [Full-text]
123. Outcomes in elderly patients following surgery for colorectal cancer in the veterans affairs health care system.
     Aliment Pharmacol Ther, 20(10): 1115-24. [Abstract] [Full-text]
124. Activation of mitochondrial lactate uptake by flavone induces apoptosis in human colon cancer cells.
     J Cell Physiol, 202(2): 379-90. [Abstract] [Full-text]
125. Laser pressure catapulting (LPC): optimization LPC-system and genotyping of colorectal carcinomas.
     J Cell Physiol, 202(2): 503-9. [Abstract] [Full-text]

© 2004-2010 Colorectal Cancer Research Today. All Rights Reserved.